Skip to main navigation Skip to search Skip to main content

Potential use of recombinant human hematopoietic growth factors in pediatrics

Research output: Contribution to journalReview articlepeer-review

Abstract

Over the last decade, the most significant advance in hematology has been the isolation, cloning, and large-scale production of hematopoietic growth factors. In vivo, these factors stimulate bone marrow progenitor cells, resulting in increased production of mature peripheral blood cells. Most of the phase III trials of these factors have involved adult patients, although a number of pediatric phase I/II trials have been reported. To date, these trials have shown that the toxicity and efficacy of these agents in children and adults are similar. Therefore, despite the paucity of pediatric data and lack of US Food and Drug Administration approval for their use in children, these factors are being used extensively in pediatrics, especially at tertiary care centers. In this article, the clinical trials of erythropoietin, granulocyte colony-stimulating factor, granulocyte-macrophage colony-stimulating factor, and interleukin-3 are reviewed.

Original languageEnglish
Pages (from-to)319-326
Number of pages8
JournalCurrent Opinion in Pediatrics
Volume4
Issue number2
DOIs
StatePublished - 1992

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health

Fingerprint

Dive into the research topics of 'Potential use of recombinant human hematopoietic growth factors in pediatrics'. Together they form a unique fingerprint.

Cite this